All In Biotech

Drug Trial Radar · NCT01431274

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD). [TOnado TM 1]

Last checked: Nov 19, 2026Latest source record: Jul 16, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,624 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,624

Actual

Start

Sep 2011

Primary completion

Sep 2013

Study completion Sep 2013

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 9, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components ( tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD).

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • tiotropium + olodaterolDrug

    fixed dose combination

  • tiotropiumDrug

    low dose

  • olodaterolDrug

    one dose only

  • tiotropiumDrug

    high dose

  • tiotropium + olodaterolDrug

    fixed dose combination

  • RespimatDevice

    Respimat inhaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3h) Response on Day 169.Time frame: 1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169.
  2. Trough FEV1 Response on Day 170.Time frame: 1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 23 h and at 23 h 50 min after inhalation of study medication on Day 170
  3. Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)Time frame: Day 169

Locations

239 sites in 25 countries. Site status is shown where the registry gives one.

  • 1237.5.01038 Boehringer Ingelheim Investigational Site

    Jasper, Alabama

  • 1237.5.01036 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 1237.5.01015 Boehringer Ingelheim Investigational Site

    Boulder, Colorado

  • 1237.5.01024 Boehringer Ingelheim Investigational Site

    Wheat Ridge, Colorado

  • 1237.5.01034 Boehringer Ingelheim Investigational Site

    Stamford, Connecticut

  • 1237.5.01003 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 1237.5.01010 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 1237.5.01027 Boehringer Ingelheim Investigational Site

    Panama City, Florida

  • 1237.5.01031 Boehringer Ingelheim Investigational Site

    O'Fallon, Illinois

  • 1237.5.01035 Boehringer Ingelheim Investigational Site

    Opelousas, Louisiana

  • 1237.5.01004 Boehringer Ingelheim Investigational Site

    Shreveport, Louisiana

  • 1237.5.01017 Boehringer Ingelheim Investigational Site

    Biddeford, Maine

  • 1237.5.01028 Boehringer Ingelheim Investigational Site

    Columbia, Maryland

  • 1237.5.01013 Boehringer Ingelheim Investigational Site

    Livonia, Michigan

  • 1237.5.01019 Boehringer Ingelheim Investigational Site

    Omaha, Nebraska

  • 1237.5.01025 Boehringer Ingelheim Investigational Site

    Larchmont, New York

  • 1237.5.01008 Boehringer Ingelheim Investigational Site

    Rochester, New York

  • 1237.5.01023 Boehringer Ingelheim Investigational Site

    Raleigh, North Carolina

  • 1237.5.01016 Boehringer Ingelheim Investigational Site

    Tabor City, North Carolina

  • 1237.5.01006 Boehringer Ingelheim Investigational Site

    Cincinnati, Ohio

  • 1237.5.01040 Boehringer Ingelheim Investigational Site

    Columbus, Ohio

  • 1237.5.01039 Boehringer Ingelheim Investigational Site

    Dayton, Ohio

  • 1237.5.01037 Boehringer Ingelheim Investigational Site

    Toledo, Ohio

  • 1237.5.01009 Boehringer Ingelheim Investigational Site

    Oklahoma City, Oklahoma

  • 1237.5.01032 Boehringer Ingelheim Investigational Site

    Charleston, Pennsylvania

  • 1237.5.01005 Boehringer Ingelheim Investigational Site

    Johnston, Rhode Island

  • 1237.5.01021 Boehringer Ingelheim Investigational Site

    Easley, South Carolina

  • 1237.5.01012 Boehringer Ingelheim Investigational Site

    Gaffney, South Carolina

  • 1237.5.01014 Boehringer Ingelheim Investigational Site

    Spartanburg, South Carolina

  • 1237.5.01029 Boehringer Ingelheim Investigational Site

    Fort Worth, Texas

  • 1237.5.01002 Boehringer Ingelheim Investigational Site

    San Antonio, Texas

  • 1237.5.01026 Boehringer Ingelheim Investigational Site

    Lynchburg, Virginia

  • 1237.5.01007 Boehringer Ingelheim Investigational Site

    Spokane, Washington

  • 1237.5.01033 Boehringer Ingelheim Investigational Site

    Tacoma, Washington

  • 1237.5.01001 Boehringer Ingelheim Investigational Site

    Morgantown, West Virginia

  • 1237.5.54010 Boehringer Ingelheim Investigational Site

    Buenos Aires, Argentina

  • 1237.5.54013 Boehringer Ingelheim Investigational Site

    Caba, Argentina

  • 1237.5.54016 Boehringer Ingelheim Investigational Site

    Caba, Argentina

  • 1237.5.54003 Boehringer Ingelheim Investigational Site

    Capital Federal, Argentina

  • 1237.5.54002 Boehringer Ingelheim Investigational Site

    Cuidad Autonoma de Buenos Airess A, Argentina

Showing 40 of 239 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.